SEC Form 4 · accession 0001209191-15-057192

PORTOLA PHARMACEUTICALS INC · PTLA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 29, 2015

Accepted (ET)

Jun 29, 2015 · 5:53 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001269021

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Jun 29, 2015	M	100,000	$3.30	A	100,000	D
Common Stock^F2,F1	Jun 29, 2015	S	71,924	$43.604	D	28,076	D
Common Stock^F3,F1	Jun 29, 2015	S	27,876	$44.242	D	200	D
Common Stock^F4,F1	Jun 29, 2015	S	200	$44.92	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F1	$3.30	Jun 29, 2015	M	100,000	D	Sep 6, 2006	Sep 6, 2016	Common Stock	100,000	70,067	D

F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2015.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.87 to $43.86, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.87 to $44.77, inclusive.
F4These shares were sold in a single transaction at a price of $44.92.